PDE4A and Other metabolic disease: Despite the robust mechanisms of action of PDE4 inhibitors, roflumilast and other selective PDE4 inhibitors have been investigated in preclinical and clinical studies for the treatment of other chronic respiratory diseases, metabolic diseases, dermatologic diseases, and neurological degenerative diseases.